YD Bio

YD Bio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of YD Bio (YDES) as of Oct 16, 2026 is -5.27 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.46 M USD — a change of 260.60% (lower).

EBITDA

-5.27 MUSD

YoY

260.60%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of YD Bio is 2025 -5.27 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of YD Bio was 2024 -1.46 M USD. It decreases by 260.60% lower compared to the previous year.

The YD Bio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-344,223.00 USD
Jan 1, 2021
-1.72 M USD
Jan 1, 2022
-2.32 M USD
Jan 1, 2023
-9,847.00 USD
Jan 1, 2024
-1.46 M USD
Jan 1, 2025
-5.27 M USD
The YD Bio EBITDA history
YEAREBITDAYoY
-5.27 MUSD+260.60%
-1.46 MUSD+14,746.45%
-9,847.00USD-99.58%
-2.32 MUSD+34.88%
-1.72 MUSD+400.36%
-344,223.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of YD Bio is -5.27 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of YD Bio changed from -1.46 M USD to -5.27 M USD, representing a 260.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) YD Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s YD Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — YD Bio

All Key Metrics — YD Bio